Lupus (SLE) trials in Germany

In Germany 39 Also abroad 354

39 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active SLE (POETYK SLE-1)
Where
Chemnitz, Cologne, Dresden, Erlangen, Lübeck, Munich, Planegg, Tuebingen
Age
18 years and over
People
147 worldwide
Run by
Bristol-Myers Squibb Services Unlimited Company
See details and how to join2022-500699-76-00 · EU 2022-500699-76-00
No phaseTaking people
Anifrolumab Malignancy and Serious Infections Study
Where
Essen
Age
18 years to 130 years
People
3,506 worldwide
Run by
AstraZeneca
See details and how to joinNCT07000110
Phase 1/2Taking people
MB-CART19.1 in refractory SLE
Where
Erlangen, Magdeburg, Tuebingen, Wuerzburg
Age
18 years and over
People
30
Run by
Miltenyi Biomedicine GmbH
See details and how to join2023-507654-33-00 · EU 2023-507654-33-00
Phase 3Enrolling by invitation
Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus Erythematosus
Where
Leipzig, Minden
Age
18 years to 75 years
People
680 worldwide
Run by
Viatris Innovation GmbH
See details and how to joinNCT06475742 · EU 2024-514354-67-00
Phase 1Taking people
A Phase 1b Basket Study Evaluating B Cell Depletion in Blood and Tissue by Etentamig or ABBV-519 in Subjects with Moderate to Severe Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), or Sjögren's Disease (SjD)
Where
Berlin
Age
18 years and over
People
20
Run by
AbbVie Deutschland GmbH & Co. KG
See details and how to join2026-526282-25-00 · EU 2026-526282-25-00
Phase 1Taking people
A Phase 1 Study of the Safety and Preliminary Efficacy of CTX112 in Adult Subjects With Refractory Autoimmune Disease.
Where
Augsburg, Cologne, Frankfurt Am Main, Hanover, Mainz
Age
18 years and over
People
51 worldwide
Run by
CRISPR Therapeutics AG
See details and how to join2024-518528-54-00 · EU 2024-518528-54-00
Phase 3Taking people
A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment
Where
Cologne, Dresden, Heidelberg, Munich
Age
18 years to 75 years
People
300 worldwide
Run by
Viatris Innovation GmbH
See details and how to joinNCT07201129 · EU 2025-522984-14-00
Phase 1Taking people
A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
Where
Berlin, Dresden, Duesseldorf, Hamburg, Kiel
Age
18 years and over
People
125 worldwide
Run by
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT07115745 · EU 2024-517681-41-00
Phase 1Taking people
A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD)
Where
Cologne, Duesseldorf, Jena, Mainz
Age
18 years to 70 years
People
44 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07371468 · EU 2025-522932-15-00
No phaseTaking people
LUPUS-BEST - Treat-to-target in Systemic Lupus Erythematosus
Where
Berlin, Dresden, Düsseldorf, Erlangen, Essen, Frankfurt am Main, Freiburg im Breisgau, Hanover, Heidelberg, Herne, Kiel, Mainz, Munich, Münster
Age
18 years and over
People
606
Run by
Heinrich-Heine University, Duesseldorf
See details and how to joinNCT05714930
Phase 1/2Taking people
A phase I/II study of CAR-expressing Allogenic iPSC derived NK cells for treatment of autoiMmune disease by B cELl depletion - CARAMEL
Where
Erlangen
Age
18 years and over
People
12
Run by
Universitaetsklinikum Erlangen AöR
See details and how to join2024-519532-16-00 · EU 2024-519532-16-00
Phase 2/3Taking people
A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101
Where
Berlin, Bochum, Hamburg, Hanover
Age
18 years and over
People
70 worldwide
Run by
Kyverna Therapeutics
See details and how to joinNCT07403188 · EU 2024-511198-31-00
Phase 1/2Taking people
MB-CART19.1 in Refractory SLE
Where
Erlangen, Magdeburg, Tübingen
Age
18 years and over
People
29
Run by
Miltenyi Biomedicine GmbH
See details and how to joinNCT06189157
Phase 1/2Taking people
CAR-T Cells in Systemic B Cell Mediated Autoimmune Disease
Where
Erlangen
Age
18 years and over
People
24
Run by
Miltenyi Biomedicine GmbH
See details and how to joinNCT06347718 · EU 2024-516819-24-00